What might have happened: the impact of interrupting entry of innovative drugs on disease outcomes in the United States

References

• Centers for Medicare and Medicaid Services. National health expenditure data. Historical. [updated 2020 December 16 cited 2021 December 16]. Available from: https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/NationalHealthAccountsHistorical
   Google Scholar
• Medina L, Sabo S, Vespa J. Living longer: historical and projected life expectancy in the United States,1960 to 2060: population estimates and projections. Current Population Reports. 25–1145 [2020 Feb cited 2021 Apr 23]. Available from: https://www.census.gov/content/dam/Census/library/publications/2020/demo/p25-1145.pdf
   Google Scholar
• Centers for Medicare and Medicaid Services. Design and development of the Diagnosis Related Group (DRG) [2019 Oct cited 2021 Apr 23] Available from: Design and development of the Diagnosis Related Group (DRG (cms.gov)
   Google Scholar
• MedicareResources,org. Medical Advantage (Part C) private health plans. [updated 2020 Dec 8 cited 2021 Apr 23]. Available from: https://www.medicareresources.org/medicare-benefits/medicare-advantage/#:~:text=Key%20takeaways,B%20benefits%2C%20except%20hospice%20services
   Google Scholar
• Bennett L. Low-value health care on downward trend in Washington state. Press Release. [updated 2019 Oct 29 cited 2021 Apr 23]. Available from: https://wahealthalliance.org/low-value-health-care-on-downward-trend-in-washington-state/
   Google Scholar
• Lee J. Covid-19, rare diseases frame drug pricing debate in congress. Bloomberg Law. [updated 2021 Apr 7 cited 2021 Apr 23]. Available from: https://news.bloomberglaw.com/health-law-and-business/covid-19-rare-diseases-frame-drug-pricing-debate-in-congress
   Google Scholar
• Hellmann J. Democrats plan crackdown on rising drug costs. The hill. [2021 Feb 21 cited 2021 Apr 23]. Available from: https://thehill.com/policy/healthcare/539724-democrats-plan-crackdown-on-rising-drug-costs
   Google Scholar
• Lower Drug Costs Now Act. HR 3, 116th congress. 2019–2021. cited 2021 Apr 26. Available from: https://www.congress.gov/bill/116th-congress/house-bill/3
   Google Scholar
• Congressional Budget Office. Effects of drug price negotiation stemming from title 1 of H.R. 3, the lower drug costs now act of 2019, on spending and revenues related to part D of medicare. Letter to the Honorable Frank Pallone Jr. [updated 2019 Oct 11 cited 2021 Mar 19]. Available from: https://www.cbo.gov/system/files/2019-10/hr3ltr.pdf?wpisrc=nl_health202&wpmm=1
   Google Scholar
• VitalTransformation. H.R. 3 - International reference pricing. Calculating the impact on the US biopharmaceutical innovation ecosystem. [2019 Nov 21 cited 2021 Apr 26]. Available from: http://vitaltransformation.com/wp-content/uploads/2020/10/PhRMA-Deck_v7.11.21.19.pdf
   Google Scholar
• Lichtenberg FR. The effect of new drugs on HIV mortality in the U.S., 1987–1998. Econ Hum Biol. 2003;1:259–266.
   PubMed Web of Science ®Google Scholar
• Lichtenberg FR. The impact of new drugs on U.S. longevity and medical expenditure, 1990–2003. Amer Econ Rev. 2007b;97:438–443.
   Web of Science ®Google Scholar
• Lichtenberg FR. The effect of new cancer drug approvals on the life expectancy of American cancer patients, 1978–2004. Econ Innovation New Technol. 2009;18:407–428.
   Google Scholar
• Lichtenberg FR. Pharmaceutical innovation and longevity growth in 30 developing and high-income countries, 2000– 2009. NBER Working Paper 18235. 2012. Accessed 14 August 2021; Available from: http://www.nber.org/papers/w18235
   Google Scholar
• Lichtenberg FR. The effect of pharmaceutical innovation on longevity: patient level evidence from the 1996–2002 medical expenditure panel survey and linked mortality public-use files. Forum Health Econ Policy. 2013a;16:1–33.
   PubMedGoogle Scholar
• Lichtenberg FR. The impact of new (orphan) drug approvals on premature mortality from rare diseases in the U.S. and France, 1999–2007. Euro J Health Econ. 2013b;14:41–56.
   PubMed Web of Science ®Google Scholar
• Lichtenberg FR. How many life-years have new drugs saved? A 3-way fixed-effects analysis of 66 diseases in 27 countries, 2000–2013. Working Paper 25483. 2019. Accessed 14 August 2021. Available from: http://www.nber.org/papers/w25483
   Google Scholar
• Buxbaum JD, Chernaw ME, Fendrick AM, et al. Contributions of public health, pharmaceuticals, and other medical care to US life expectancy changes, 1990–2015. Health Aff (Millwood). 2020 Dep;39:1546–1556.
   Google Scholar
• Cutler DM, Ghosh K, Messer KL, et al. Explaining the slowdown in medical spending growth among the elderly, 1999–2012. Health Aff (Millwood). 2019 Feb;38:222–229.
   PubMed Web of Science ®Google Scholar
• Global Health Data Exchange. Global burden of disease study 2017 (GBD 2017) data resources. BD results tool. [updated 2019 Jul 23 cited 2021 Apr 23]. Available from. http://ghdx.healthdata.org/gbd-2017
   Google Scholar
• Salomon JA, Haagsma JA, Davis A, et al. Disability weights for the global burden of disease 2013 study. Lancet Glob Health. 2015 Nov 1;3:e712–23.
   PubMed Web of Science ®Google Scholar
• Penfold RB, Zhang F. Use of interrupted time series analysis in evaluating health care quality improvements. Acad Pediatr. 2013;13:S38–S44.
   PubMed Web of Science ®Google Scholar
• Bernal JL, Cummins S, Gasparrini A. Interrupted time series regression for the evaluation of public health interventions: a tutorial. Int J Epidemiol. 2017 Feb 1;46:348–355.
   PubMed Web of Science ®Google Scholar
• Flint AC, Conell C, Klingman JG, et al. Impact of increased early statin administration on ischemic stroke outcomes: a multicenter electronic medical record intervention. J Am Heart Assoc. 2016;5:e003413.
   PubMed Web of Science ®Google Scholar
• Perrett KP, Jachno K, Nolan TM, et al. Association of rotavirus vaccination with the incidence of type 1 diabetes in children. JAMA Pediatr. 2019;173:280–282.
   PubMed Web of Science ®Google Scholar
• Islam N, Sharp SJ, Chowell G, et al. Physical distancing interventions and incidence of coronavirus disease 2019: natural experiment in 149 countries. BMJ. 2020 Jul 15;370:m2743.
   PubMedGoogle Scholar
• Williams AJ, Henley W, and Frank J. Impact of abolishing prescription fees in Scotland on hospital admissions and prescribed medicines: an interrupted time series evaluation. BMJ Open. 2018 Dec 18; 8:e021318.
   PubMed Web of Science ®Google Scholar
• GBD. Disease and injury incidence and prevalence collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2017;392:1789–1858. [2018 Nov 10].
   Web of Science ®Google Scholar
• Krishnan E, Lingala B, Bruce B, et al. Disability in rheumatoid arthritis in the era of biological treatments. Ann Rheum Dis. 2012;71:213–218.
   PubMed Web of Science ®Google Scholar
• Lichtenberg FR. The impact of pharmaceutical innovation on longevity and medical expenditure in France, 2000–2009. Econ Hum Biol. 2014;13:107–127.
   PubMed Web of Science ®Google Scholar
• Rosamond WD, Chambless LE, Heiss G, et al. Twenty-two-year trends in incidence of myocardial infarction, coronary heart disease mortality, and case fatality in 4 US communities, 1987–2008. Circulation. 2012 Apr 17;125:1848–1857.
   PubMedGoogle Scholar
• Howlader N, Noone AM, Krapcho M, et al. eds. SEER cancer statistics review. 1975–2016. Bethesda MD: National Cancer Institute; based on November 2018 SEER data submission, posted to the SEER web site. 2019 April. [citedApr 2021] https://seer.cancer.gov/csr/1975_2016/
   Google Scholar
• Caswell-Jin JL, Plevritis SK, Tian L, et al. Change in survival in metastatic breast cancer with treatment advances: meta-analysis and systematic review. JNCI Cancer Spectr. 2018 Nov;2: ky062.
   PubMed Web of Science ®Google Scholar
• Marcus JL, Chao CR, Leyden WA, et al. Narrowing the gap in life expectancy between HIV-infected and HIV-uninfected individuals with access to care. J Acquir Immune Defic Syndr. 2016 Sep 1;73:39–46.
   PubMed Web of Science ®Google Scholar
• Burrows NR, Li Y, Geiss LS. Incidence of treatment for end-stage renal disease among individuals with diabetes in the U.S. continues to decline. Diabetes Care. 2010 Jan;33:73–77.
   PubMed Web of Science ®Google Scholar
• Burrows NR, Hora I, Geiss LS, et al. Incidence of end-stage renal disease attributed to diabetes among persons with diagnosed diabetes - United States and Puerto Rico, 2000–2014. MMWR Morb Mortal Wkly Rep. 2017 Nov 3;66:1165–1170.
   PubMed Web of Science ®Google Scholar
• Louie GH, Ward MM. Changes in the rates of joint surgery among patients with rheumatoid arthritis in California, 1983–2007. Ann Rheum Dis. 2010 May;69:868–871.
   PubMed Web of Science ®Google Scholar
• Pennington B, Davis S. Mapping from the health assessment questionnaire to the EQ-5D: the impact of different algorithms on cost-effectiveness results. Value Health. 2014;17:762–771.
   PubMed Web of Science ®Google Scholar
• Lichtenberg FR. Effects of new drugs on overall health spending: Frank Lichtenberg responds. Health Affairs. 2007a;26:887–890.
   Web of Science ®Google Scholar
• Shahrbaf FG, Assadi F. Drug-induced renal disorders. J Renal Injury Prev. 2015 Sep 1;4:57–60.
   PubMedGoogle Scholar
• Teschke R, Danan G. Worldwide use of rucam for causality assessment in 81,856 idiosyncratic Dili and 14,029 hili cases published 1993-mid 2020: a comprehensive analysis. Medicines (Basel). 2020 sep 29;7:62.
   Google Scholar